Did you mean?
Search Results - Showing 12 - 24 Of 61
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.webp "Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agents in advanced castration resistant prostate cancer.nnShe reports that in cohort A (patients with BRCA1, BRCA2 or ATM genes) progression free survival was over double in favour of the olaparib and in the overall population of cohort A and cohort B (alterations in other genes involved in DNA repair) there were similar trends.nnProf Hussain be")
⏲ 3 min 98 sec ✓ 30-Sep-2019
_rucaparib-and-olaparib-two-new-treatments-approved-for-advanced-prostate-cancer-124-pcri.webp "Prostate Cancer Research Institute")
⏲ 5 minutes 15 seconds 👁 1.8K
_parp-inhibitors-for-prostate-cancer.webp "Cleveland Clinic")
_targeted-therapy-recent-advances-in-prostate-cancer-from-esmo-2019.webp "Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA), Prof Noel Clarke (The Christie NHS Foundation Trust, Manchester, UK), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Matthew Smith (Massachusetts General Hospital Cancer Center, Boston, USA) discuss the key developments presented at ESMO 2019 on targeted therapies in prostate cancer. nnThe panel discuss the latest data from the STAMPEDE trial and the use of docetaxel in high-volume disease versus lo")
_parp-inhibitors-for-the-treatment-of-metastic-castration-resistant-prostate-cancer.webp "VJOncology")
⏲ 1 minute 35 seconds 👁 109
_olaparib-plus-abiraterone-for-mcrpc-are-biomarkers-necessary.webp "VJOncology")
_asco-2020-prostate-cancer-highlights.webp "Prof Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs a virtual discussion with Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Dr Kim Chi (BC Cancer Research Centre, Vancouver, Canada) and Prof Amit Bahl (University Hospitals Bristol, Bristol, UK) about the main prostate cancer highlights from ASCO 2020. nnProf Merseburger provides an overview of the latest developments presented around PSMA imaging. He outlines two prospective phase III trials that")
_olaparib-plus-abiraterone-could-be-a-new-first-line-treatment-option-for-mcrpc-124-fred-saad.webp "Medicine Matters oncology")
⏲ 3 minutes 41 seconds 👁 184
_9234abiraterone-saved-my-life-9234-124-alfred39s-prostate-cancer-story.webp "The Institute of Cancer Research, London")
_latest-developments-in-prostate-cancer-updates-from-titan-card-and-the-era-of-personalised-medicine.webp "Prof Karim Fizazi (Institut Gustave Roussy, Paris, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the latest updates in prostate cancer from ASCO GU 2020 in San Francisco. nnProf Merseburger describes the latest data from the TITAN trial, in which the time to second progression (PFS2) result was positive, with the occurrence of no new safety signals. He also explains th")
⏲ 9 min 18 sec ✓ 15-Feb-2020
_response-to-olaparib-among-men-with-brca-1-2-or-atm-mutated-prostate-cancer.webp "PracticeUpdate")
⏲ 5 minutes 7 seconds 👁 102
_niraparib-and-abiraterone-acetate-for-metastatic-castration-resistant-prostate-cancer.webp "ASCOcancer")
⏲ 2 minutes 59 seconds 👁 1.1K
![[+]](/images/menu.gif){kind=small}